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Abstract
Objective
To determine that children with arterial ischemic stroke (AIS) due to an identifiable arterio-
pathy are distinct from those without arteriopathy and that each arteriopathy subtype has
unique and recognizable clinical features.
Methods
We report a large, observational, multicenter cohort of children with AIS, age 1 month to 18
years, enrolled in the International Pediatric Stroke Study from 2003 to 2014. Clinical and
demographic differences were compared by use of the Fisher exact test, with linear step-up
permutation min-p adjustment for multiple comparisons. Exploratory analyses were conducted
to evaluate differences between cases of AIS with and without arteriopathy and between
arteriopathy subtypes.
Results
Of 2,127 children with AIS, 725 (34%) had arteriopathy (median age 7.45 years). Arteriopathy
subtypes included dissection (27%), moyamoya (24.5%), focal cerebral arteriopathy–
inflammatory subtype (FCA-i; 15%), diffuse cerebral vasculitis (15%), and nonspecific arte-
riopathy (18.5%). Children with arteriopathic AIS were more likely to present between 6 and 9
years of age (odds ratio [OR] 1.93, p = 0.029) with headache (OR 1.55, p = 0.023), multiple
infarctions (OR 2.05, p < 0.001), sickle cell anemia (OR 2.9, p = 0.007), and head/neck trauma
(OR 1.93, p = 0.018). Antithrombotic use and stroke recurrence were higher in children with
arteriopathy. Among arteriopathy subtypes, dissection was associated with male sex, older age,
headache, and anticoagulant use; FCA-i was associated with hemiparesis and single infarcts;
moyamoya was associated with seizures and recurrent strokes; and vasculitis was associated
with bilateral infarctions.
Conclusion
Specific clinical profiles are associated with cerebral arteriopathies in children with AIS. These
observations may be helpful indicators in guiding early diagnosis and defining subgroups who
may benefit most from future therapeutic trials.
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Cerebral arteriopathies are reported in 30% to 50% of all
children with arterial ischemic stroke (AIS).1,2 Most child-
hood cerebral arteriopathies are characterized either by
dissection or by stenosis and irregularity of the intracranial
arteries such as moyamoya and focal cerebral arteriopathy
(FCA) of childhood. FCA is characterized by acute, uni-
lateral, segmental stenosis of ≥1 large arteries of the
anterior circulation2–5 and is presumed to be inflammatory
in origin,2–4,6 although the angiographic appearance can be
mimicked by intracranial dissection.7 One-third of cases of
FCA may demonstrate initially progressive arterial nar-
rowing, but by definition, arterial narrowing does not
progress beyond 3 to 6 months after stroke.8 Most impor-
tant, childhood cerebral arteriopathies are associated with
a 5-fold higher risk of stroke recurrence9 and poor out-
come.10 Therefore, their improved understanding is crucial
to the development of immediate and preventive treatment
strategies.
The difficulty in identifying and classifying childhood ce-
rebral arteriopathies is a major limitation, relating often to
the imaging technique, inability to consistently and accu-
rately identify the diagnosis at presentation, and lack of
standardized terminology and diagnostic criteria.1,2,8,11,12
Recent cohorts of cerebral arteriopathy have come from the
International Pediatric Stroke Study (IPSS),1 in which
arteriopathies are classified using gradually developed and
refined consensus-based definitions.1,5 Recently, a substudy
of the IPSS rereviewed neurovascular imaging of their
arteriopathic cases and noted that a substantial proportion
(up to 30%) of arteriopathies in their cohort remained
challenging to classify.2 Such challenges are a frequent oc-
currence in clinical practice, suggesting that a clinical fin-
gerprint may be helpful in the diagnosis and classification of
childhood cerebral arteriopathies, especially early in the
disease course when the arteriopathy has not declared its
clinical course (progression, stabilization, improvement).
We hypothesized that children with AIS due to an identi-
fiable arteriopathy are distinct from those without arterio-
pathy and that the arteriopathy subtypes are distinct.
Methods
Study design
The IPSS is a prospective, multicenter, observational reg-
istry that enrolls and follows up children with ischemic
stroke and related conditions. The IPSS currently com-
prises >300 investigators (representing 24 countries across
5 continents) and a web-based master database housed at
the study coordinating center, The Hospital for Sick Chil-
dren, Toronto, Ontario, Canada.13 The IPSS design has
been previously published.1,10 The present analysis in-
cludes children with AIS with and without an underlying
cerebral arteriopathy who were enrolled between January
2003 and July 2014 (including previously reported 667
cases enrolled from 2003 to 2007 in the IPSS1 and 355 cases
from 2010 to 2014 coenrolled in the IPSS and an IPSS
substudy, the Vascular Effects of Infection in Pediatric
Stroke [VIPS]2).
Standard protocol approvals, registrations,
and patient consents
As per IPSS policy, each site investigator obtained and
maintained research ethics approval according to that inves-
tigator’s institutional policy to enroll and study eligible cases.
Study Population
Inclusion criteria were age from 1 month to 18 years and
AIS presenting with acute onset of neurologic deficit and
a radiologic pattern consistent with arterial territory is-
chemia. Arteriopathy was defined a priori as any abnor-
mality on vascular imaging (stenosis, irregularity, banding,
pseudoaneurysm, dissection flap) except isolated vessel
occlusion, which may be due to an embolus rather than
a primary blood vessel abnormality.9 Children without
arteriopathy had either idiopathic AIS (no obvious risk
factor or etiology) or well-described nonarteriopathic risk
factor for AIS (e.g., cardioembolic stroke). The presence of
arteriopathy and its subtype were determined by the en-
rolling IPSS site investigators and clinicians involved in the
child’s care using the IPSS consensus-based definitions.5
Because a centralized review of radiographic films could not
be performed due to the lack of an imaging repository in the
IPSS dataset, we validated the arteriopathy diagnosis and
subtype classification on the basis of the radiographic data
available through the free text comment boxes in the IPSS
dataset. In cases with unclear descriptions, more data were
requested and obtained from the submitting IPSS site
investigators (figure 1A). The authors further refined the
arteriopathy classification referencing recent literature14
through consensus at 3 teleconferences and 1 face-to-face
meeting.
The refined arteriopathy subtypes included 5 mutually exclu-
sive subtypes: (1) FCA, inflammatory type (FCA-i), which in-
cluded idiopathic or presumed inflammatory FCA, transient
cerebral arteriopathy, and postvaricella arteriopathy cases2,3,5,6,15;
(2) dissection (extracranial, intracranial); (3) moyamoya (pri-
mary moyamoya disease, moyamoya syndrome secondary to
Glossary
AIS = arterial ischemic stroke; CI = confidence interval; FCA = focal cerebral arteriopathy; FCA-i = focal cerebral arteriopathy,
inflammatory type; IPSS = International Pediatric Stroke Study;OR = odds ratio; PSOM = Pediatric Stroke OutcomeMeasure;
VIPS = Vascular Effects of Infection in Pediatric Stroke.
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other conditions); (4) diffuse cerebral vasculitis (infectious,
noninfectious); and (5) nonclassifiable/nonspecific arterio-
pathies labeled as other arteriopathy (congenital, acquired)
(figure 1B). Lack of sufficiently detailed vascular imaging limited
our ability to further subcategorize vasculitis. We excluded chil-
dren with arteriopathy but without stroke.
Figure 1 Study population
(A) International Pediatric Stroke Study (IPSS) cohort of children with arterial ischemic stroke (AIS) and cerebral arteriopathies. (B) IPSS cohort of children with
AIS associated with arteriopathy. FCA-i = focal cerebral arteriopathy–inflammatory subtype.
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Data collection and abstraction
Study data were collected at each site by the IPSS site inves-
tigators and entered into the web-based IPSS database. The
variables studied included demographic data (age at stroke
diagnosis, sex, geographic region, race), clinical features
(hemiparesis, visual field deficit, speech deficit, ataxia, de-
creased level of consciousness, headache, seizures, prior/
concurrent thromboembolic event), radiographic information
(circulation, stroke laterality, number of infarcts, hemorrhage),
risk factors for stroke (cardiac disorder, underlying chronic
disease, acute systemic disease, acute and chronic head/neck
disease, family history of stroke), neuroimaging features (lo-
cation and number of infarcts), antithrombotic treatments
(classified as antiplatelet or anticoagulant agents), and out-
comes.Management decisions for each case were guided by the
published pediatric stroke management guidelines16 but varied
according to the treating physician’s preferences and local in-
stitutional protocols. Outcomes included neurologic deficits
at discharge, stroke recurrence, case fatality, and standardized
stroke outcomes at 1 year and last follow-up visit that were
collected through a parental Recurrence and Recovery
Questionnaire17,18 (mean duration 2.3 years), and Pediatric
Stroke Outcome Measure (PSOM)17,18 (mean duration
2.5 years). Poor outcome was defined as a PSOM score >1.
Statistical methods
Analyses were performed with SAS version 9.4 statistical soft-
ware (SAS Institute, Cary, NC). Descriptive analysis, including
proportions, means, and frequencies, was used to define par-
ticipant characteristics. Intracranial dissection, extracranial
dissection, FCA-i, moyamoya, and vasculitis were included in
the subtype comparison exploratory analyses. Cases with
multiple arteriopathies or missing data were excluded from the
analysis. Cases with dissection that could not be classified as
either intracranial or extracranial dissection were excluded
from the arteriopathy subtype analysis. Multiple comparisons
(arteriopathy- vs non–arteriopathy-associated AIS, arterio-
pathy subtypes) were performed with the Fisher exact test with
linear step-up permutationmin-p adjustment. Values of α ≤0.05
were considered significant. Significant variables were included
in a stepwise multiple logistic regression analysis. Poisson re-
gression was used to test the difference of treatment over time,
and logistic regression and χ2 tests were used as necessary to
describe and measure associations involving multilevel cate-
gorical variables.
Data availability
All data used for analysis are presented in the tables and figures
in this article. Data will be shared after ethics approval if
requested by other investigators for purposes of replicating the
results.
Results
A total of 4,294 children were enrolled in the IPSS during the
study period. We identified 2,274 (53%) children, 1 month to
18 years of age, with AIS. Of these, 2,127 (93%) children
fulfilled the current study inclusion criteria. Of this cohort, 725
(34%) children were identified as having AIS due to arterio-
pathy, and 1,402 (66%) children had AIS due to non-
arteriopathic causes (figure 1A and table 1). In 2,127 children
with AIS, nonarteriopathic risk factors (either single or multiple
in a study participant) included cardioembolic disorders (29%),
chronic diseases (31%), acute systemic illnesses (26%), acute
head or neck infections/trauma (21%), chronic head or neck
disorders (8%), and family history of stroke (14%) (table 2). In
725 children with arteriopathy, arteriopathy subtypes were
categorized as craniocervical dissection in 193 (27%), moya-
moya in 177 (24%), FCA-i in 110 (15%), diffuse cerebral
vasculitis in 111 (15%), and other arteriopathy in 134 (19%)
(figure 1B). Although dedicated vascular imaging was reported
in 1,409 of 2,127 (66%) cases (74% noncardiac and 26% car-
diac AIS), this number is underreported due to themissing data
in the dataset. Of the 718 (34%) cases with no vascular imaging
Table 1 Demographic profile of children with AIS with
and without arteriopathy
Variables
Arteriopathy,
n (%)
No arteriopathy,
n (%)
Age at index stroke, median
(IQR), ya,b
7.45 (3.68–12.76) 4.6 (1.11–12.18)
0–3 146/725 (20) 573/1,399 (41)
3–6 145/725 (20) 203/1,399 (14)
6–9 137/725 (19) 130/1,399 (9)
9–12 88/725 (12) 135/1,399 (10)
12–15 113/725 (16) 161/1,399 (11)
15–18 96/725 (13) 197/1,399 (14)
Male sex 423/725 (58) 806/1,402 (57)
Geographic region
Africa 0/725 (0) 3/1,402 (<1)
Asia 22/725 (3) 91/1,402 (6)
Australia 38/725 (5) 65/1,402 (5)
Europe 129/725 (18) 219/1,402 (16)
North Americaa 506/725 (70) 923/1,402 (66)
South America 30/725 (4) 101/1,402 (7)
Race
Blacka 73/492 (15) 86/993 (9)
White 321/492 (65) 648/993 (65)
Other 98/492 (20) 259/993 (26)
Abbreviations: AIS = arterial ischemic stroke; IQR = interquartile range.
a Fisher exact test showed statistically significant association with the pres-
ence of arteriopathy before multiple-comparisons adjustment.
b Significant association of age and arteriopathy: age as continuous variable
(p < 0.0001, odds ratio [OR] 1.04 per unit increase) and as categorical vari-
able (using 15–18 years as reference, those 0–3 years old are less likely to
have arteriopathy [p < 0.0001, OR 0.52] and those 6–9 years old are more
likely to have arteriopathy [p < 0.0001, OR 2.16]).
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Table 2 Clinical profile of children with AIS with and without arteriopathy
Variables
Arteriopathy,
n (%)
No arteriopathy,
n (%)
Hemiparesisa 573/707 (81) 991/1,321 (75)
Visual field deficit 76/568 (13) 141/1,032 (14)
Dysarthriaa 163/639 (25) 193/1,155 (17)
Ataxiaa 77/705 (11) 82/1,349 (6)
Altered consciousness 252/685 (37) 514/1,298 (40)
Headachea 285/637 (45) 324/1,092 (30)
Seizures 158/691 (23) 439/1,313 (33)
Prior/concurrent thromboembolisma 123/629 (19) 142/1,233 (11)
Anterior circulation involvement 434/645 (67) 810/1,224 (66)
Posterior circulation involvement 141/645 (22) 278/1,224 (23)
Both circulation involvement 70/645 (11) 136/1,224 (11)
Right-sided infarctiona 251/639 (39) 412/1,218 (34)
Left-sided infarction 232/639 (36) 559/1,218 (46)
Bilateral infarctiona 156/639 (25) 247/1,218 (20)
Multiple infarctsa 309/578 (53) 415/1,097 (38)
Single infarcts 269/578 (47) 682/1,097 (62)
Hemorrhagic infarct 55/566 (10) 178/1,085 (16)
Cardiac disease 98/723 (13) 512/1,402 (37)
Underlying chronic disease 242/723 (33) 415/1,402 (30)
Connective tissue diseasea 17/723 (2) 17/1,402 (1)
Malignancy 9/723 (1) 23/1,402 (2)
Sickle cell anemiaa 60/723 (8) 37/1,402 (3)
Presence of syndrome 49/723 (7) 86/1,402 (6)
Prothrombotic state 66/723 (9) 131/1,402 (9)
Acute systemic disease 147/723 (20) 405/1,402 (29)
Acute head and neck diseasea 168/723 (23) 275/1,402 (20)
Significant infectionb 18/723 (2) 59/1,402 (4)
Noniatrogenic traumaa 85/723 (12) 100/1,402 (7)
Chronic head and neck disorder 53/723 (7) 110/1,402 (8)
Family history of stroke 100/687 (14) 173/1,303 (13)
Treatment with anticoagulant agent 229/694 (33) 393/1,331 (30)
Treatment with antiplatelet agent 270/694 (39) 467/1,331 (35)
Treatment with both anticoagulant and antiplatelet agents 52/694 (7) 66/1,331 (5)
Unspecified antithrombotic treatment 44/694 (6) 59/1,331 (4)
Abbreviation: AIS = arterial ischemic stroke.
a Fisher exact test showed statistically significant association with the presence of arteriopathy before multiple-comparisons adjustment.
b Significant infection defined as meningitis or mastoiditis; nonsignificant infections included sinusitis, otitis media, and pharyngitis.
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indicated in the IPSS dataset, 164 (23%) were labeled as having
an arteriopathy by the site investigators. As stated in the
Methods section, arteriopathy cases with insufficient in-
formation or unclear diagnosis were rereviewed by the study
investigators for any radiology information in the dataset, and
those with no radiologic data to support the arteriopathy di-
agnosis were sent to the reporting site investigator for review of
their radiology information to confirm the diagnosis and type of
arteriopathy (figure 1A).
Tables 1 and 2 lists the demographic and clinical features of
AIS and specifies all variables that were significantly associated
with arteriopathy (p ≤ 0.05) before multiple-comparison
adjustment. Results (p values and odds ratios [ORs]) from
multivariable analysis are stated in the section below (table 3).
Arteriopathic vs nonarteriopathic AIS
Children with arteriopathy-associated AIS were older com-
pared to children with nonarteriopathic causes (median age
7.45 years [interquartile range 3.68–12.76] vs 4.6 years
[interquartile range 1.11–12.18 years], p < 0.0001 [z = 7.05]),
with the highest likelihood of AIS due to an arteriopathic
cause occurring in 6- to 9-year-old children (p = 0.029, OR
1.93, 95% confidence interval [CI] 1.1–3.5) (figure 2A).
There were equal proportions of boys (58% [423 of 725]
arteriopathic AIS vs 57% [806 of 1,402] nonarteriopathic
Table 3 Demographic and clinical associations with arteriopathy in childhood AISa
Variables
Available data Univariate analysis Multivariable analysisb
No. OR (CI) p Value OR (CI) p Value
Age (ref = 15–18 y), yc 2,124
0–<3 0.52 (0.39–0.71) <0.0001 0.93 (0.51–1.69) 0.810
3–<6 1.47 (1.06–2.03) 0.020 1.72 (0.97–3.04) 0.063
6–<9 2.16 (1.54–3.04) <0.0001 1.93 (1.07–3.51) 0.029
9–12 1.34 (0.93–1.92) 0.116 1.81 (0.97–3.36) 0.061
12–<15 1.44 (1.02–2.03) 0.036 1.70 (0.92–3.14) 0.087
Race (ref = other) 1,485
Black 2.24 (1.52–3.31) <0.0001
White 1.31 (1.00–1.71) 0.049
Hemiparesis (ref = none) 2,028
Bilateral 1.01 (0.59–1.75) 0.960
Unilateral 1.45 (1.15–1.81) 0.001
Speech deficit (ref = none) 1,794
Aphasia 1.25 (0.98–1.60) 0.073
Dysarthria 1.83 (1.43–2.34) <0.0001
Both 1.27 (0.58–2.81) 0.552
Headache 1,729 1.92 (1.57–2.35) <0.0001 1.55 (1.06–2.25) 0.023
Prior/concurrent thromboembolism 1,862 1.87 (1.43–2.43) <0.0001
Multiple infarction 1,675 1.89 (1.54–2.31) <0.0001 2.05 (1.45–2.91) <0.0001
Non iatrogenic trauma (ref = none) 2,125 1.74 (1.29–2.36) 0.0004 1.93 (1.12–3.31) 0.018
Sickle cell anemia 2,125 3.34 (2.19–5.08) <0.0001 2.90 (1.32–6.34) 0.007
Treated with antithrombotic agent 2,025 2.11 (1.65–2.70) <0.0001 1.87 (1.11–3.15) 0.018
Deficit at discharge 1,864 1.45 (1.14–1.83) 0.002
Stroke recurrence 1,819 3.17 (2.38–4.21) <0.0001 2.37 (1.46–3.84) 0.0004
Abbreviation: AIS = arterial ischemic stroke; CI = confidence interval; OR = odds ratio; ref = referent.
a Multiple logistic regression analysis. Includes significantly associated variables after multiple-comparisons adjustment.
b Area under the curve 70%.
c Age, as either continuous or categorical variable, was significant in univariate analysis. In multivariable analysis, age as categorical variable was used due to
the nonlinear relationship between age and many of the other variables. For example, trauma history is more common in young children, lower in middle
childhood, and then higher again in teenagers (U-shaped curve relationship).
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AIS) and whites (65% [321 of 725] arteriopathic AIS vs 65%
[648 of 993] nonarteriopathic AIS) in each group (table 1).
Geographic differences were observed, with Asia (19%) and
South America (23%) having smaller proportions of arterio-
pathic AIS compared to other continents (35%–37%, p <
0.0003 [χ2 = 21, df = 4]) (figure 3). However, these geo-
graphic differences were not significant on multivariable
analysis.
Children with arteriopathy associated AIS were more likely to
present with headache (p = 0.023, OR 1.55, 95% CI 1.0–2.2)
and multiple infarctions (p < 0.0001, OR 2.05, 95% CI
1.4–2.9) than those with nonarteriopathic AIS. Sickle cell
anemia (p = 0.007, OR 2.9, 95% CI 1.3–6.3) and head or neck
trauma (p = 0.018, OR 1.93, 95%CI 1.1–3.3) were risk factors
for AIS associated with arteriopathy (table 2).
Children with arteriopathy-associated AIS were more likely to
be treated with antithrombotic treatment (86% [595 of 694]
arteriopathic vs 74% [985 of 1,331] nonarteriopathic AIS, p =
0.018, OR 1.87). Although not statistically significant, an in-
crease in the use of antithrombotic treatment over time was
noted (73% in 2003–2006, 78% in 2007–2010, and 83% in
2011–2014, p = 0.082) (table 3). We observed significant
differences in treatment patterns between geographic
regions/continents in arteriopathic AIS (p = 0.006 [χ2 = 14,
df = 4]). The proportion of cases of AIS with arteriopathy
receiving antithrombotic treatment was highest in Australia
(97%), Europe (87%), and North America (86%) compared
to Asia (74%) and South America (65%) (figure 3).
Discharge outcome was available in 88% and longitudinal
outcomes were available in 37% of cases (mean duration 2.4
years, range 3 months–12.1 years). Children with arteriopathy-
associated AIS had a higher likelihood of deficits at discharge
(82% [538 of 659] arteriopathic vs 75% [909 of 1,205]
nonarteriopathic AIS, p = 0.002). Longitudinal outcomes,
measured by the PSOM, were not different between the 2
groups both at 1 year (52% [63 of 121] arteriopathic vs 51%
[109 of 214] nonarteriopathic AIS) and at last measured
PSOM (57% [159 of 279] vs 52% [266 of 510]). Overall
ischemic stroke recurrence risk was 12% (226 of 1,819), with
significantly higher risk in arteriopathic compared to non-
arteriopathic AIS (21% [131 of 614] arteriopathic vs 8% [95
of 1,205] nonarteriopathic AIS, p = 0.0004, OR 2.37, 95% CI
1.5–3.8) (table 3).
Figure 2 Association of age
(A) Association of age and arteriopathy in childrenwith arterial ischemic stroke (AIS). (B) Age distribution in childrenwith AIS by arteriopathy type. FCA-i = focal
cerebral arteriopathy–inflammatory subtype.
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AIS characteristics by arteriopathy subtype
Each arteriopathy subtype demonstrated interesting differ-
ences compared to other arteriopathies (figure 2B and tables
e-1 and e-2, doi.org/10.5061/dryad.7d7wm37r3). Cases with
intracranial dissection were typically >15 years of age (27%, p
= 0.035, OR 2.3, 95% CI 1.1–5.1), while extracranial dissec-
tion was associated with male sex (80%, p = 0.001, OR 3.17,
95% CI 1.6–6.4). With age as a continuous variable, a per-unit
increase in age was associated with an increased risk for in-
tracranial dissection (p < 0.0001, OR 1.18), FCA-i (p = 0.015,
OR 0.95), or moyamoya (p = 0.026, OR 0.96). Black race was
common with moyamoya (24% vs 3%–11%, p = 0.002, OR
3.81, 95% CI 1.6–8.8) and white race with FCA-i (81% vs
49%–77%, p = 0.009, OR 2.79, 95% CI, 1.3–6.0).
In univariate analysis, statistically significant variations in geo-
graphic distribution of arteriopathy subtypes were observed.
Post hoc analysis looking at proportion of subtypes within each
region was conducted to account for the variability in the
number of sites enrolling in IPSS per region (of 86 sites: South
America 9 [10%], North America 54 [63%], Europe 15 [17%],
Australia 2 [2%], and Asia 6 [7%]). Compared to other sub-
types, FCA-i diagnosis was highest in Europe (37 of 82 [45%],
p < 0.0001 [χ2 = 47, df = 4]) and Australia (16 of 35 [45%],
p = 0.001 [χ2 = 18, df = 4]), and moyamoya diagnosis was
highest in North America (138 of 364 [38%], p < 0.0001 [χ2 =
45, df = 4]). No significant differences in the proportion of
subtypes were observed in South America and Asia (table e-1,
doi.org/10.5061/dryad.7d7wm37r3).
In a comparison of arteriopathy subtypes (table e-2, doi.org/10.
5061/dryad.7d7wm37r3), clinical presentations that were
more prevalent with a specific arteriopathy subtype included
head or neck trauma with both intracranial (38%, p < 0.0003,
OR 4.19, 95% CI 1.9–9.0) and extracranial (37%, p < 0.0001,
OR 5.02, 95% CI 2.5–10.3) dissection; headache (78%, p =
0.0004, OR 4.20, 95% CI 1.9–9.2) with intracranial dissection;
posterior circulation involvement (52%, p < 0.0001, OR 3.65,
95% CI 1.9–6.7) with extracranial dissection; seizures (31%, p
= 0.004, OR 2.62, 95% CI 1.3–5.1), bilateral infarction (37%, p
< 0.0004, OR 3.97, 95% CI 1.9–8.4), and anterior circulation
involvement (80%, p < 0.0007, OR 3.5, 95% CI 1.7–7.2) with
moyamoya; unilateral hemiparesis (88%, p = 0.02, OR 2.95,
95% CI 1.1–7.5) and single infarcts (76%, p < 0.0001, OR 5.31,
95% CI 2.6–10.8) with FCA-i; and bilateral infarction (36%,
p = 0.03, OR 1.71, 95%CI 1.0–2.8) and acute systemic findings
(37%, p < 0.0001, OR 3.58, 95% CI 2.2–5.9) with vasculitis.
A higher proportion of cases with dissection were treated with
an anticoagulation (62% extracranial [p = 0.0008, OR 2.79,
95% CI 1.5–5.1] and 53% intracranial dissection [p = 0.02
significant only in univariate analysis] vs 15%–39% other
arteriopathy subtypes), whereas a higher proportion of cases
with moyamoya received antiplatelet treatment (55% moya-
moya [p = 0.001, OR 2.80, 95% CI 1.1–4.1] vs 29%–37%
other arteriopathy subtypes).
Both discharge and long-term outcomes were not statis-
tically different among the arteriopathy subtypes, except
Figure 3 Distribution of arteriopathy and first reported treatment of arteriopathy by geographic region
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that moyamoya arteriopathy was associated with the highest
odds of having recurrent ischemic strokes (33%, p = 0.01,
OR 2.17, 95% CI 1.1–4.1). In cases with moyamoya, stroke
recurrence may have been affected by the timing of re-
vascularization surgery. However, dates of surgery were in-
consistently available, and this information could not be
presented.
Discussion
We present the largest series of childhood AIS patients with
and without arteriopathy, comparing their presentation, risk
factors, treatments, and outcome. The proportion of children
with arteriopathic AIS in our sample, both total and across
geographic regions, is largely similar to what has previously
been reported.1,19 Lower frequencies of arteriopathic AIS in
Asia and South America may have been due to underdiagnosis
because MRI and other vascular imaging techniques are less
available in these regions, although this finding might be an
artifact of limited sites participating in the IPSS and needs
further evaluation. Higher prevalences of young children with
arteriopathy and male sex in childhood AIS have been pre-
viously reported1,20 and are confirmed by this study. Recently,
VIPS investigators reanalyzed their 355 cases with AIS and
found 127 (36%) children with a radiologically confirmed
arteriopathy. In their cohort, moyamoya disease more fre-
quently affected children <8 years of age, FCA-i affected chil-
dren between 8 and 15 years of age, and dissection affected all
ages.19 In the current IPSS cohort of children (including VIPS
cases), cases with FCA-i were more likely to present between 3
and 6 years of age and cases with dissection were more com-
mon at >12 years of age, differing somewhat from the smaller
VIPS dataset. In total, the bimodal distribution seen in all
arteriopathies may be secondary to an increased prevalence of
FCA-i andmoyamoya among younger children and intracranial
dissection among older children. These findings may be par-
ticularly important in future outcome studies because recovery
from stroke is likelymodified by age due to the location-specific
vulnerability and plasticity in the developing brain.21,22
Many previously described clinical features and observations
are confirmed by the current IPSS dataset, including the fre-
quent occurrence of deficits at discharge, stroke recurrence, and
multiple ischemic infarctions in children with arteriopathy.9,10
The last is likely accounted for by arteriopathic involvement of
multiple arteries or arterial segments and recurrent artery-to-
artery thromboembolism. In addition, in children with sickle
cell anemia, the sickle-associated arteriopathy combines with an
increased baseline recurrent stroke risk from sickle cell anemia.
Other study findings included frequent involvement of anterior
circulation with moyamoya arteriopathy23 and posterior cir-
culation with extracranial dissection.24,25 Furthermore, the
finding of a high proportion of cases with seizures and bilateral
infarction in children with moyamoya is also not entirely sur-
prising because moyamoya arteriopathy involves bilateral ar-
terial territories and causes varying ages of ischemic strokes as
the disease slowly progresses.23,26 On the same note, the
presence of single infarcts with resultant hemiparesis in cases
with FCA-i and bilateral infarction and acute systemic findings
in cases with vasculitis can be explained by their etiopathologic
involvement (typical unilateral focal arterial involvement in
cases with FCA-i and bilateral diffuse arterial involvement in
association with infectious or inflammatory conditions in cases
with vasculitis).
Considering the large multinational IPSS dataset, the findings
of the current study are generalizable to and highly repre-
sentative of the childhood AIS population.While male sex and
black race have previously been reported as risk factors for
dissection and childhood AIS in general,20,27 to the best of our
knowledge, the very high percentage of male patients with
extracranial dissection (80%) in our study is the highest
reported to date. This finding may be secondary to increased
head trauma in male patients,27 although biological sex dif-
ferences may also have contributed. A study comparing cases
of pediatric ischemic stroke to controls has demonstrated
a 1.3-fold increase in the risk for cerebral thromboembolism
with each 1-nmol/L increase in testosterone in boys.28 Fur-
thermore, recent descriptions of V3 vertebral dissections in an
exclusively male cohort29 also suggest increased susceptibility
to extracranial dissections among male patients. The pro-
portion of cases of FCA in our cohort is smaller than reported
previously (15% vs up to 25%)2 and may be due to a lack of
vascular imaging in all our patients. Geographic differences
noted in this study are also interesting. Moyamoya diagnosis
had the highest proportion in North America, whereas FCA-i
diagnosis had the highest proportion in Europe and Australia.
These findings may be related to the association between
moyamoya and sickle cell anemia (p < 0.0001) and between
sickle cell anemia and black race (p < 0.0001) in conjunction
with the higher number of black children in North America
(of 371 with AIS with race and region data, 45 of 48 [94%] of
black children were in North America). The association of
moyamoya and black race does not hold while controlling for
the presence of sickle cell anemia. Of 25 patients with sickle
cell anemia AIS with race data, 5 of 5 (100%) with vasculitis
and 18 of 20 (90%) with moyamoya were black children
(Fisher exact test p = 0.99).
The association of headache with arteriopathic childhood AIS
is a clinically relevant finding in the current cohort.30 While
headache in childhood stroke has been reported, particularly
with craniocervical arterial dissection,24,30 this study demon-
strates that the association is broad (across arteriopathic
stroke types) and robust, with very high rates of headache in
both extracranial (63%) and intracranial (78%) dissections.
On the basis of these data, it is important for clinicians to
consider and exclude dissection early in children with AIS
who present with significant headache.30
The high rate of antithrombotic use acutely in children with
arteriopathic AIS noted in the current cohort is similar to
the previously reported increased use of antithrombotic
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treatment over time.10,31 This finding is largely reflective of
current clinical practice and is likely driven by the increased
awareness of high recurrence risk in cases with arteriopathy.
The high rate of anticoagulation use acutely in children with
extracranial dissection is reflective of the pediatric stroke
management guidelines in use during the study period.16,30
The high rate of anticoagulation use in intracranial dissection
(53%) is surprising, however, and may be based on a few
studies that suggested that anticoagulation is safe in cases of
childhood arteriopathy.32 Of note, despite published man-
agement guidelines for childhood stroke, ≈20% of cases of
AIS received no acute antithrombotic treatment. It is unclear
from these data whether this finding is due to a lack of ad-
herence to published guidelines or, more likely, the with-
holding of antithrombotic therapy in circumstances when
therapy may not be clearly indicated such as brain tumor,
several intracranial infections, or sickle cell disease–associated
strokes. This indicates an area in which further research, ed-
ucation, and outreach are required.
Despite the significant association between arteriopathy and
risk for recurrent strokes, we found no statistically significant
difference in short- and long-term outcomes between arte-
riopathic and nonarteriopathic AIS. The large amount of
missing outcome data and the lack of longer follow-up du-
ration to see the impact of stroke recurrence likely contrib-
uted to these nonsignificant results.
Limitations of this study include those typically associated
with large cohort studies. Data may have been overreported or
underreported. This finding is particularly germane to our
follow-up results in that patients with a higher degree of
medical impairment are more likely to seek medical care and
may be overrepresented in follow-up data. These study par-
ticipants were enrolled at academic centers, likely leading to
referral bias; for example, AIS due to cardiac disease may be
overrepresented due to the concentration of children with
congenital heart disease at those centers.
In this study, few variables had significant amounts of missing
data; namely, race was missing in 63% and PSOM data were
missing in 37%. However, for most variables as listed in tables
1 and 2, the percentage of missing data in the current dataset is
within the acceptable ranges for a large dataset (median 4.8%,
mean 7.9%, range 0%–24.8%). While the large patient volume
is strength of our cohort, all radiographic data are based on
available radiology reports and the site investigator’s in-
terpretation, without centralized confirmation. Because the
interrater reliability is only modest among trained raters,11
imprecise classification of the AIS etiology and arteriopathy
subtypes may have confounded our results. Furthermore, al-
though the numbers are small, dedicated vascular imaging was
not performed in all noncardiac cases of AIS. Other problems
with validity and reliability may exist in these data.
Children with arteriopathic stroke have differentiating fea-
tures compared to those without arteriopathic stroke and
between each arteriopathy subtype. These observations may
be helpful in guiding clinicians in managing arteriopathic
cases of AIS by choosing appropriate investigations (e.g.,
head and neck vascular imaging) and treatment strategies.
The evaluation of arteriopathy subtypes in our analysis may
be particularly useful because initial radiographic diagnosis
of arteriopathy does not always accurately determine the
final classification; indeed, almost one-third of arteriopathies
are challenging to classify. Among the 355 VIPS cases with
AIS, 127 (35.7%) had definite arteriopathy and 34 (9.5%)
had possible arteriopathy. Of those with definite arterio-
pathy, only 109 (30.7%) cases could be classified with high
certainty into an arteriopathy subtype.2 Another example,
intracranial dissection, may be diagnosed on conventional
angiogram performed outside of the acute phase of stroke,
and 6% of patients with initial diagnosis of FCA progress to
the diagnosis of moyamoya.8 Therefore, these observations
may assist clinicians in the earlier diagnoses of specific arte-
riopathy subtypes and appropriate treatment strategies. The
results will also serve to define patient subgroups who are at
higher risk for adverse outcomes and are likely to benefit most
from future therapeutic trials. Specifically, these findings may
assist in identifying pediatric patients for inclusion in steroid
trials in the FCA-i population, studies evaluating the efficacy of
antithrombotic management in extracranial dissection (in
particular, utility of anticoagulant therapy because pediatric
patients reportedly have higher rates for recurrent stroke
compared to adult patients),25 and trials examining the role of
long-term transfusion in sickle cell disease.
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